- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03121014
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Damiano Rondelli, MD
- Phone Number: 312-413-3547
- Email: drond@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois at Chicago
-
Contact:
- Damiano Rondelli, MD
- Phone Number: 312-413-3547
- Email: drond@uic.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65 years
Patients with AML or MDS who meet the following criteria:
a. Relapsed or refractory AML (including AML in CR2)
b. Poor-risk AML in first remission, with remission defined as <5% bone marrow blasts morphologically:
- AML arising from MDS or a myeloproliferative disorder, or secondary AML
- Poor risk molecular features including presence of FLT3 internal tandem duplication mutation.
Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (> 3 abnormalities), inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7
c. Primary refractory disease
d. MDS with at least one of the following poor-risk features:
- Poor-risk cytogenetics including 3q abnormalities, 7/7q minus or complex cytogenetics (>3 abnormalities)
- Current or previous INT-2 or high IPSS score
- Treatment-related MDS
- MDS diagnosed before age 21 years
- Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy
- Life-threatening cytopenias, including those requiring regular PRBC or platelet transfusions e. CML with a history of accelerated or blast phase
Patients must have a related or unrelated peripheral blood stem cell donor as follows:
- Sibling donor must be a 6/6 match for HLA-A, -B at intermediate (or higher) resolution and -DRB1 at high resolution using DNA based typing
- Unrelated donors must be at least 7/8 match at HLA-A, -B, -C and DRB1 at high resolution using DNA-based typing
Exclusion criteria:
Presence of significant co morbidity as shown by:
- Left ventricular ejection fraction < 50%
- Creatinine clearance <30ml/min
- Bilirubin > 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST > 5 x ULN
- FEV1 and FVC < 50% of predicted or DLCO <50% of predicted once corrected for anemia
f. Karnofsky score <70 (appendix C)
g. Hematopoietic cell transplantation comorbidity index >3
h. Active viral hepatitis or HIV infection
j. Cirrhosis
- Pregnancy
- Patients unable to sign informed consent
- Patient who have previously received radiation to >20% of bone marrow containing areas.
4. DONOR ELIGIBILITY AND SELECTION
4.1. Donor Selection
Donor evaluation and selection is by standard for normal clinical practice. No study procedures are to be performed on donors. All donors must be willing to donate peripheral blood stem cells and meet institutional or NMDP criteria for donation.
The following prioritization will be used when selecting donors:
- When possible, an HLA compatible sibling will be used as a donor.
- For patients who do not have an HLA compatible sibling, an unrelated donor will be used
- 8/8 matched unrelated donors are preferred over single antigen mismatched donors.
If more than one potential volunteer unrelated donor is considered suitable further selection of the most suitable donor is at the discretion of the treating physician. The following serves only as a guide for prioritization:
- Age of donor (18-24 > 25-34 > 35-44 > 45+)
- Sex and parity of donor (male > female, nulliparous female > parous, multiparous female)
- Cytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- > CMV+)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient Treatment
Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors).
In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1.
On day 0, the stem cell product will be infused according to BMT unit policy.
Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate.
Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
|
40 mg/m^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
Other Names:
targeting a 4800μM/min/ day from day -5 through day -2
Other Names:
0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
Other Names:
dose of 3Gy on days -3, -2 and -1
Day 0 according to BMT unit policy
The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2.
Dose will be adjusted to target trough levels of 5-15 ng/mL.
More information is available in the protocol document.
Other Names:
5mg/m^2 on Day 1, 5 mg/m^2 on Days 3, 6 and 11
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse free survival of approximately 30% in high-risk patients conditioned with the Fludarabine/ Busulfan regimen
Time Frame: Up to 1 year
|
Using a Simon 2 stage optimal design with α of 0.05 and power of 0.8, 15 patients will be enrolled in the first stage.
If greater than 5 patients survive to 1 year without relapse the study will continue into stage 2. Recruitment will then continue to a total of 46 patients.
In this expanded cohort, if a total of 18 or more patients survive to 1 year without relapse, the treatment will be judged efficacious and worthy of further study.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse free survival
Time Frame: Up to 1 year
|
It will be estimated and reported with 90% confidence intervals.
The proportion of patients who are alive at 1-year will also be estimated with a 90% exact binomial confidence interval.
|
Up to 1 year
|
Overall survival
Time Frame: Up to 1 year
|
It will be estimated and reported with 90% confidence intervals.
The proportion of patients who are alive at 1-year will also be estimated with a 90% exact binomial confidence interval.
|
Up to 1 year
|
Transplant related mortality rate
Time Frame: Up to 1 year
|
After accrual of 10 patients, analysis will be performed to ensure that the mortality rate does not exceed 30%.
By calculation of confidence intervals to ensure the TRM not exceed 30%, accrual would be halted if n= 6 of 10 (lower bound of the exact, one-sided 90% CI is 35.4%).
|
Up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Damiano Rondelli, MD, University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Fludarabine
- Methotrexate
- Tacrolimus
- Busulfan
- Thymoglobulin
Other Study ID Numbers
- 2017-0001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Fludarabine
-
National Institute of Arthritis and Musculoskeletal...CompletedPsoriasis | Arthritis, PsoriaticUnited States
-
Nantes University HospitalCyceronNot yet recruiting
-
Naoyuki G. Saito, M.D., Ph.D.WithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Emory UniversityCompletedSickle Cell Disease | Bone Marrow TransplantationUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedSystemic Lupus Erythematosus | Glomerulonephritis | Lupus NephritisUnited States
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceCompletedUntreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma PatientsFrance
-
University of Illinois at ChicagoCompletedAcute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic LeukemiaUnited States
-
Zhujiang HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsUnknownLeukemia Relapse | Chronic Graft-versus-host-disease
-
Massachusetts General HospitalTerminatedMultiple Myeloma | Hodgkin Disease | Non Hodgkin's LymphomaUnited States
-
NCIC Clinical Trials GroupCompleted